Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1345

1.

The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.

Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ; Consistency Lot Study Group for ProQuad.

Pediatr Infect Dis J. 2006 Jul;25(7):615-22.

PMID:
16804432
2.

Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.

Nolan T, McIntyre P, Roberton D, Descamps D.

Vaccine. 2002 Dec 13;21(3-4):281-9.

PMID:
12450703
3.

Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, Prieler A, Maurer H, Bisanz H, Tornieporth N, Descamps D, Willems P.

Pediatr Infect Dis J. 2006 Jan;25(1):12-8.

PMID:
16395096
4.
5.

Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.

Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P.

Pediatr Infect Dis J. 2008 Aug;27(8):724-30. doi: 10.1097/INF.0b013e318170bb22. Erratum in: Pediatr Infect Dis J. 2013 Apr;32(4):e163.

PMID:
18600190
6.

Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.

Shinefield H, Black S, Digilio L, Reisinger K, Blatter M, Gress JO, Brown ML, Eves KA, Klopfer SO, Schödel F, Kuter BJ.

Pediatr Infect Dis J. 2005 Aug;24(8):665-9.

PMID:
16094217
7.

Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.

Shinefield H, Black S, Williams WR, Marchant C, Reisinger K, Stewart T, Meissner HC, Guerrero J, Klopfer SO, Xu J, Schödel F, Kuter BJ; Dose Selection Study Group for Proquad.

Pediatr Infect Dis J. 2005 Aug;24(8):670-5. Erratum in: Pediatr Infect Dis J. 2005 Nov;24(11):983.

PMID:
16094218
8.

Combination measles, mumps, rubella and varicella vaccine.

Arbeter AM, Baker L, Starr SE, Levine BL, Books E, Plotkin SA.

Pediatrics. 1986 Oct;78(4 Pt 2):742-7.

PMID:
3763291
9.
10.

Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.

Gillet Y, Steri GC, Behre U, Arsène JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, Willems P.

Vaccine. 2009 Jan 14;27(3):446-53. doi: 10.1016/j.vaccine.2008.10.064. Epub 2008 Nov 11.

PMID:
19007835
11.

Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children.

Shinefield HR, Black SB, Staehle BO, Matthews H, Adelman T, Ensor K, Li S, Chan I, Heyse J, Waters M, Chan CY, Vessey SJ, Kaplan KM, Kuter BJ; Kaiser Permanente Medical Team for Varivax.

Pediatr Infect Dis J. 2002 Jun;21(6):555-61.

PMID:
12182381
13.

Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2010 May 7;59(RR-3):1-12.

14.

Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.

Parment PA, Svahn A, Rudén U, Bråkenhielm G, Storsaeter J, Akesson L, Linde A.

Scand J Infect Dis. 2003;35(10):736-42.

PMID:
14606613
15.

Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.

Leung JH, Hirai HW, Tsoi KK.

Expert Rev Vaccines. 2015;14(8):1149-57. doi: 10.1586/14760584.2015.1057572. Epub 2015 Jun 16.

PMID:
26081133
16.

Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.

Halperin SA, Ferrera G, Scheifele D, Predy G, Stella G, Cuccia M, Douha M, Willems P.

Vaccine. 2009 May 5;27(20):2701-6. doi: 10.1016/j.vaccine.2009.02.044. Epub 2009 Feb 24.

PMID:
19428882
17.

Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.

Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E, Xu J, Hartzel J, Evans B, Digilio L, Schödel F, Brown ML, Kuter B; 013 Study Group for ProQuad.

Pediatr Infect Dis J. 2006 Apr;25(4):287-92.

PMID:
16567978
18.

Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.

Shinefield HR, Black S, Kuter BJ.

J Infect Dis. 2008 Mar 1;197 Suppl 2:S152-5. doi: 10.1086/522126.

PMID:
18419390
19.

The combination measles, mumps, rubella and varicella vaccine in healthy children.

Arbeter AM, Baker L, Starr SE, Plotkin SA.

Dev Biol Stand. 1986;65:89-93.

PMID:
3030864
20.

Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

Knuf M, Zepp F, Helm K, Maurer H, Prieler A, Kieninger-Baum D, Douha M, Willems P.

Eur J Pediatr. 2012 Mar;171(3):463-70. doi: 10.1007/s00431-011-1569-4. Epub 2011 Sep 21.

PMID:
21935584

Supplemental Content

Support Center